<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291628</url>
  </required_header>
  <id_info>
    <org_study_id>Socks</org_study_id>
    <nct_id>NCT01291628</nct_id>
  </id_info>
  <brief_title>Prevention of Capecitabine Induced Hand and Foot Syndrome</brief_title>
  <official_title>A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome
      called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness
      and painful sores. Quite often the drug dose is reduced to suboptimal level due to this side
      effect. There is no way to prevent or an effective way to treat this side effect. The
      investigators aim is to investigate whether wearing socks which contain copper fibers may
      prevent or alleviate the patient symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome
      called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness
      and painful sores. Quite often the drug dose is reduced to suboptimal level due to this side
      effect. There is no way to prevent or an effective way to treat this side effect. Our aim is
      to investigate whether wearing socks which contain copper fibers may prevent or alleviate the
      patient symptoms.

      The patients will use socks containing copper-oxide impregnated fibers which are sold in the
      Pharma stores without physician's prescription.(EPA numbers 8454-2, 8454-3 from April 30
      2009).

      Drug Toxicity and skin reaction will be documented.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>skin feet toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>within the first year from starting Capecitabine use</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>socks containing copper-oxide fibers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>socks containing copper-oxide fibers</intervention_name>
    <description>The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.</description>
    <arm_group_label>socks containing copper-oxide fibers</arm_group_label>
    <other_name>Cupron company EPA :84542-2, 84542-3 from April 30 2009.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of stage IV cancer - treated with Capecitabine

        Exclusion Criteria:

          -  Any patient who can not sign an informed consent

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rinat Yerushalmi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center, Affiliated to Tel-Aviv University, Tel-Aviv, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aaron Sulkes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center affilated to Tel-Aviv University, Tel-Aviv, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rinat Yerusahlmi, MD</last_name>
    <phone>972-3-8024</phone>
    <email>rinaty@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aaron Sulkes, MD</last_name>
    <phone>972-3-7940</phone>
    <email>asulkes@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center, Oncology department</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rinat Yerusahlmi, MD</last_name>
      <phone>972-3-8024</phone>
      <email>rinaty@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rinat Yerusahlmi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aaron Sulkes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shtemmer Salomon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baruch Brenner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ofer Purim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Neiman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noa Choraro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eyal Fenig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yulia Kundel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shulamith Rizel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luisa Bonila, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001 Apr 15;19(8):2282-92.</citation>
    <PMID>11304782</PMID>
  </reference>
  <reference>
    <citation>Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001 Nov 1;19(21):4097-106.</citation>
    <PMID>11689577</PMID>
  </reference>
  <reference>
    <citation>Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest. 2002;20(1):3-10.</citation>
    <PMID>11853000</PMID>
  </reference>
  <reference>
    <citation>Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL; Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002 Apr;13(4):566-75.</citation>
    <PMID>12056707</PMID>
  </reference>
  <reference>
    <citation>Borkow G, Gabbay J. Putting copper into action: copper-impregnated products with potent biocidal activities. FASEB J. 2004 Nov;18(14):1728-30. Epub 2004 Sep 2.</citation>
    <PMID>15345689</PMID>
  </reference>
  <reference>
    <citation>Ueda K, Morita J, Yamashita K, Komano T. Inactivation of bacteriophage phi X174 by mitomycin C in the presence of sodium hydrosulfite and cupric ions. Chem Biol Interact. 1980 Feb;29(2):145-58.</citation>
    <PMID>6444372</PMID>
  </reference>
  <reference>
    <citation>Karlström AR, Levine RL. Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5552-6.</citation>
    <PMID>2062837</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Cho H, Ryu SE, Choi MU. Effects of metal ions on the activity of protein tyrosine phosphatase VHR: highly potent and reversible oxidative inactivation by Cu2+ ion. Arch Biochem Biophys. 2000 Oct 1;382(1):72-80.</citation>
    <PMID>11051099</PMID>
  </reference>
  <reference>
    <citation>Cervantes C, Gutierrez-Corona F. Copper resistance mechanisms in bacteria and fungi. FEMS Microbiol Rev. 1994 Jun;14(2):121-37. Review.</citation>
    <PMID>8049096</PMID>
  </reference>
  <reference>
    <citation>Sen CK, Khanna S, Venojarvi M, Trikha P, Ellison EC, Hunt TK, Roy S. Copper-induced vascular endothelial growth factor expression and wound healing. Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1821-7.</citation>
    <PMID>11959648</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>rinat yerushalmi</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>Capecitabine</keyword>
  <keyword>Hand and foot syndrome</keyword>
  <keyword>Socks</keyword>
  <keyword>Copper</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hand-Foot Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

